Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Should You Buy?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up before the market opened on Wednesday . The stock had previously closed at $10.21, but opened at $10.81. Telix Pharmaceuticals shares last traded at $10.9050, with a volume of 56,813 shares.

Analyst Ratings Changes

A number of analysts recently weighed in on TLX shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.12.

Telix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm’s 50-day simple moving average is $10.12 and its 200-day simple moving average is $8.75.

Insider Buying and Selling at Telix Pharmaceuticals

In other news, CEO Christian Behrenbruch purchased 33,435 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was purchased at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the acquisition, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. This trade represents a 0.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its position in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares in the last quarter. XTX Topco Ltd purchased a new stake in Telix Pharmaceuticals in the fourth quarter worth about $89,000. Bank of America Corp DE lifted its stake in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. OLD Mission Capital LLC bought a new position in Telix Pharmaceuticals during the 4th quarter worth about $111,000. Finally, XY Capital Ltd purchased a new position in Telix Pharmaceuticals during the 1st quarter valued at about $120,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.